EHAB
Enhabit, Inc. NYSE Listed Jun 23, 2022$13.78
Mkt Cap $705.9M
52w Low $6.47
94.3% of range
52w High $14.22
50d MA $13.74
200d MA $10.06
P/E (TTM)
-151.8x
EV/EBITDA
10.7x
P/B
1.2x
Debt/Equity
0.9x
ROE
-0.9%
P/FCF
7.1x
RSI (14)
—
ATR (14)
—
Beta
1.08
50d MA
$13.74
200d MA
$10.06
Avg Volume
1.5M
Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. As of March 31, 2022, it operated in 252 home health agencies and 99 hospice agencies across 34 states. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was incorporated in 2014 and is headquartered in Dallas, Texas. As of July 1, 2022, Enhabit, Inc. operates as a standalone company.
6688 N. Central Expressway · Dallas, TX 75206 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | AMC | 0.14 | 0.14 | +0.0% | 13.61 | -0.1% | +0.0% | +0.0% | +0.4% | -0.1% | +0.1% | — |
| Nov 5, 2025 | AMC | 0.12 | 0.17 | +41.7% | 8.21 | +2.9% | -6.1% | -3.2% | -3.4% | -2.7% | -1.9% | — |
| Aug 6, 2025 | AMC | 0.10 | 0.13 | +30.0% | 6.77 | +4.1% | +15.2% | +12.6% | +7.5% | +11.4% | +11.8% | — |
| May 7, 2025 | AMC | 0.07 | 0.10 | +42.9% | 8.20 | +5.6% | +18.2% | +25.4% | +27.6% | +27.7% | +29.0% | — |
| Mar 5, 2025 | AMC | 0.07 | 0.04 | -42.9% | 8.54 | -8.8% | -6.1% | -0.1% | +1.5% | -1.1% | +0.0% | — |
| Nov 6, 2024 | AMC | 0.04 | 0.03 | -21.1% | 7.91 | -2.5% | +0.1% | -0.3% | +1.3% | -3.8% | -3.8% | — |
| Aug 6, 2024 | AMC | 0.06 | 0.07 | +16.7% | 9.89 | -5.2% | -14.1% | -13.9% | -14.5% | -17.4% | -10.9% | — |
| May 8, 2024 | AMC | 0.05 | 0.07 | +40.0% | 9.70 | -22.1% | -14.5% | -14.0% | -10.9% | -6.8% | -10.7% | — |
| Mar 6, 2024 | AMC | 0.03 | 0.06 | +128.0% | 7.86 | +20.0% | +22.1% | +31.6% | +25.8% | +32.6% | +37.9% | — |
| Nov 7, 2023 | AMC | 0.06 | 0.03 | -48.3% | 8.55 | +0.2% | +16.0% | +10.3% | +8.8% | +7.6% | +14.2% | — |
| Aug 9, 2023 | AMC | 0.14 | 0.04 | -71.4% | 13.70 | -6.3% | -13.8% | -16.1% | -12.6% | -17.4% | -16.3% | — |
| May 9, 2023 | AMC | 0.12 | 0.09 | -25.0% | 13.51 | +0.3% | -8.7% | -5.3% | -9.5% | -10.3% | -12.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6 | TD Cowen | Downgrade | Buy → Hold | — | $13.61 | $13.60 | -0.1% | +0.0% | +0.4% | -0.1% | +0.1% | +0.0% |
| Feb 24 | UBS | Downgrade | Buy → Neutral | — | $13.60 | $13.59 | -0.1% | -0.3% | -0.1% | +0.0% | +0.1% | -0.1% |
| Feb 23 | Jefferies | Downgrade | Buy → Hold | — | $11.09 | $13.58 | +22.5% | +22.6% | +22.3% | +22.5% | +22.6% | +22.7% |
| Feb 23 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $11.09 | $13.58 | +22.5% | +22.6% | +22.3% | +22.5% | +22.6% | +22.7% |
| Jan 22 | Oppenheimer | Upgrade | Perform → Outperform | — | $10.74 | $11.10 | +3.4% | +3.1% | +0.5% | -0.1% | -3.4% | -3.9% |
| Jan 13 | TD Cowen | Upgrade | Hold → Buy | — | $10.19 | $11.11 | +9.0% | +7.5% | +6.0% | +6.9% | +3.2% | +2.4% |
| Jan 8 | UBS | Upgrade | Neutral → Buy | — | $9.51 | $10.04 | +5.6% | +7.2% | +4.8% | +7.2% | +15.1% | +13.6% |
| Aug 8 | UBS | Maintains | Neutral → Neutral | — | $7.80 | $7.72 | -1.0% | -2.3% | -6.7% | -3.3% | -2.9% | -5.3% |
| Dec 9 | Jefferies | Upgrade | Hold → Buy | — | $7.73 | $8.17 | +5.7% | +13.2% | +11.1% | +10.3% | +10.2% | +10.2% |
| Nov 19 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $7.14 | $7.05 | -1.3% | +1.8% | +4.5% | +4.6% | +5.9% | +6.7% |
| Jun 27 | BofA Securities | Maintains | Underperform → Underperform | — | $8.49 | $8.39 | -1.2% | +0.9% | +5.1% | +3.1% | +3.2% | +3.2% |
| May 14 | Leerink Partners | Upgrade | Underperform → Market Perform | — | $8.64 | $8.91 | +3.1% | +4.6% | +0.2% | -3.4% | -4.5% | +3.6% |
| May 9 | Jefferies | Downgrade | Buy → Hold | — | $9.70 | $7.56 | -22.1% | -14.5% | -14.0% | -10.9% | -6.8% | -10.7% |
| Mar 11 | TD Cowen | Maintains | Market Perform → Market Perform | — | $10.34 | $10.14 | -1.9% | -4.4% | +0.8% | +4.8% | +4.9% | +6.5% |
| Mar 7 | UBS | Upgrade | Sell → Neutral | — | $7.86 | $9.43 | +20.0% | +22.1% | +31.6% | +25.8% | +32.6% | +37.9% |
| Mar 7 | Oppenheimer | Maintains | Perform → Perform | — | $7.86 | $9.43 | +20.0% | +22.1% | +31.6% | +25.8% | +32.6% | +37.9% |
| Mar 6 | Jefferies | Maintains | Buy → Buy | — | $7.92 | $7.91 | -0.1% | -0.8% | +21.2% | +30.6% | +24.9% | +31.6% |
| Aug 11 | Credit Suisse | Maintains | Neutral → Neutral | — | $11.81 | $11.51 | -2.5% | -2.6% | +1.4% | -4.1% | -2.9% | -1.5% |
| Jul 17 | Goldman Sachs | Maintains | Neutral → Neutral | — | $12.63 | $12.19 | -3.5% | +0.1% | +0.6% | +6.9% | +8.4% | +13.7% |
| Mar 16 | Goldman Sachs | Maintains | Neutral → Neutral | — | $14.25 | $14.06 | -1.3% | -0.8% | -5.1% | -6.5% | -3.9% | -3.6% |
| Feb 17 | Citigroup | Maintains | Neutral → Neutral | — | $15.74 | $15.73 | -0.1% | -0.6% | -0.6% | -0.2% | +0.2% | -2.3% |
| Feb 16 | Credit Suisse | Maintains | Neutral → Neutral | — | $15.99 | $15.67 | -2.0% | -1.6% | -2.1% | -2.1% | -1.8% | -1.4% |
| Dec 13 | CJS Securities | Maintains | Market Perform → Perform | — | $13.97 | $13.87 | -0.7% | -0.4% | +0.4% | +0.2% | -3.7% | -4.8% |
| Dec 8 | UBS | Maintains | Sell → Sell | — | $14.59 | $14.02 | -3.9% | -6.2% | -5.1% | -4.2% | -4.6% | -3.9% |
| Dec 6 | Stifel | Maintains | Buy → Buy | — | $13.68 | $14.05 | +2.7% | +6.7% | +6.7% | +0.1% | +1.2% | +2.1% |
| Nov 4 | Credit Suisse | Maintains | Neutral → Neutral | — | $12.60 | $12.54 | -0.5% | +0.4% | +3.6% | +3.2% | +1.3% | +1.3% |
| Oct 14 | Oppenheimer | Maintains | Perform → Perform | — | $12.76 | $12.69 | -0.5% | -2.6% | +0.5% | +4.9% | +3.1% | +0.7% |
| Aug 30 | Jefferies | Maintains | Buy → Buy | — | $15.04 | $15.43 | +2.6% | +6.2% | +10.4% | +2.5% | +2.5% | +10.4% |
| Aug 25 | Credit Suisse | Maintains | Neutral → Neutral | — | $15.85 | $15.50 | -2.2% | -3.3% | -5.4% | -5.1% | +0.8% | +4.7% |
| Aug 18 | Citigroup | Maintains | Neutral → Neutral | — | $14.30 | $13.98 | -2.2% | -1.6% | +1.8% | +7.8% | +10.1% | +10.8% |
| Jul 13 | BofA Securities | Maintains | Underperform → Underperform | — | $18.80 | $17.98 | -4.4% | -4.3% | -8.0% | -1.4% | -1.4% | -2.3% |
No insider trades available.
8-K
Enhabit, Inc. -- 8-K Filing
Enhabit faces shareholder litigation alleging its proxy statement contained material misrepresentations regarding management financial projections and Goldman Sachs' valuation analyses, creating potential legal and financial exposure.
May 5
8-K
Unknown — 8-K Filing
The merger is progressing on schedule with regulatory approval secured, suggesting the deal will close in Q2 2026 as planned, reducing execution risk for shareholders awaiting the transaction completion.
Apr 16
8-K · 7.01
! Medium
Enhabit, Inc. -- 8-K 7.01: Regulation FD Disclosure
Enhabit disclosed material non-public information to select parties, potentially creating information asymmetry and raising concerns about fair market access to critical company updates for all shareholders.
Mar 5
8-K · 1.01
! Medium
Enhabit, Inc. -- 8-K 1.01: Financing / Debt Agreement
Enhabit secured a five-year credit facility with SOFR-based variable interest rates, providing flexible financing for operations while exposing the company to interest rate fluctuations.
Mar 4
8-K · 5.02
!!! Very High
Enhabit, Inc. -- 8-K 5.02: Executive Change
Enhabit appointed Ryan Solomon as Chief Financial Officer, replacing Collin McQuiddy who resigned as Senior Vice President, signaling potential leadership transition that could impact financial strategy execution.
Feb 27
8-K
Enhabit, Inc. -- 8-K Filing
Enhabit's merger agreement cancels out-of-the-money employee stock options while preserving in-the-money options and RSUs, diluting existing shareholders through the equity consideration structure of the transaction.
Feb 23
8-K · 7.01
! Medium
Enhabit, Inc. -- 8-K 7.01: Regulation FD Disclosure
Enhabit disclosed material information to select parties under Regulation FD, signaling potential market-moving news that all investors should now have access to through this filing.
Feb 12
Data updated apr 25, 2026 6:41am
· Source: massive.com